Reason for request
Reassessment
Summary of opinion
Favourable opinion for reimbursement in the treatment of HIV-1 infection only in adults and adolescents above 12 years of age weighing at least 40 kg:
- who are treatment-naive, with a CD4 count of more than 200/mm3, a viral load (VL) of less than 500,000 copies/mL and with no known or suspected resistance to either of the two drugs;
- previously treated, with a stable VL < 50 copies/mL for at least one year, a CD4 count of more than 350/mm3 and with no known or suspected resistance to either of the two drugs.
Unfavourable opinion for reimbursement in the other situations covered by the MA indication.
Clinical Benefit
| Substantial |
The clinical benefit of DOVATO (dolutegravir/lamivudine) is substantial only in adults and adolescents above 12 years of age
weighing at least 40 kg:
- who are treatment-naive, with a CD4 count of more than 200/mm3, a viral load (VL) of less than 500,000 copies/mL and with no known or suspected resistance to either of the two drugs;
- previously treated, with a stable VL < 50 copies/mL for at least one year, a CD4 count of more than 350/mm3 and with no known or suspected resistance to either of the two drugs.
|
| Insufficient |
The clinical benefit is insufficient to justify public funding cover in the other populations of the MA. |
Clinical Added Value
| minor |
Updating of the reimbursement scope in view of the long-term follow-up data from the GEMINI 1 and 2 studies and in line with current HAS recommendations, does not modify the clinical added value level of DOVATO (dolutegravir/lamivudine) according to the opinion of 8 January 2020:
- minor clinical added value (CAV IV) in the treatment of HIV-1 infection in adults and adolescents above 12 years of age who are treatment-naive, with a CD4 count of more than 200/mm3, a VL of < 500,000 copies/mL and with no known or suspected resistance to either of the two drugs,
- no clinical added value (CAV V) in the treatment of patients infected with HIV-1, who are previously treated and virologically suppressed, compared to the proprietary medicinal product JULUCA.
|
| no clinical added value |
Updating of the reimbursement scope in view of the long-term follow-up data from the GEMINI 1 and 2 studies and in line with current HAS recommendations, does not modify the clinical added value level of DOVATO (dolutegravir/lamivudine) according to the opinion of 8 January 2020:
- minor clinical added value (CAV IV) in the treatment of HIV-1 infection in adults and adolescents above 12 years of age who are treatment-naive, with a CD4 count of more than 200/mm3, a VL of < 500,000 copies/mL and with no known or suspected resistance to either of the two drugs,
- no clinical added value (CAV V) in the treatment of patients infected with HIV-1, who are previously treated and virologically suppressed, compared to the proprietary medicinal product JULUCA.
|
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
mmFPtXQm547sJgY6
